Header Logo

DANIEL D KARP

TitleProfessor
InstitutionMD Anderson
DepartmentInvestigational Cancer Therapeutics
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chang JY, Xu X, Shroff GS, Comeaux NI, Li W, Rodon Ahnert J, Karp DD, Dumbrava EE, Verma V, Chen A, Welsh J, Hong DS. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer. 2024 Oct 09; 12(10). PMID: 39384194; PMCID: PMC11474930.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol. 2024 Jul 31; 8(1):166. PMID: 39085400; PMCID: PMC11291882.
      Citations:    
    3. Gouda MA, Shunyakova J, Naing A, Dumbrava E, Hong DS, Yuan Y, Yang P, Myers A, Liang Y, Peng J, Karp D, Tsimberidou AM, Rodon J, Yap TA, Piha-Paul SA, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open. 2024 Jun; 9(6):103486. PMID: 38914452; PMCID: PMC11258623.
      Citations:    Translation:HumansCTClinical Trials
    4. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525. PMID: 38297981; PMCID: PMC10994248.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    5. Emery SE, Rosenheim JA, Chaplin-Kramer R, Sharp R, Karp DS. Leveraging satellite observations to reveal ecological drivers of pest densities across landscapes. Sci Total Environ. 2024 May 10; 924:171591. PMID: 38485019.
      Citations:    Fields:    Translation:Animals
    6. Coleman N, Stephen B, Fu S, Karp D, Subbiah V, Ahnert JR, Piha-Paul SA, Wright J, Fessahaye SN, Ouyang F, Yilmaz B, Meric-Bernstam F, Naing A. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med. 2024 Feb; 13(3):e6877. PMID: 38400671; PMCID: PMC10891443.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    7. Lema C, Cheng KW, Anderson DM, Miller CC, Karp DD, McPherson DD, Kolar SSN. Simultaneous submission of seven CTSA proposals: UM1, K12, R25, T32-predoctoral, T32-postdoctoral, and RC2: strategies, evaluation, and lessons learned. J Clin Transl Sci. 2024; 8(1):e33. PMID: 38384924; PMCID: PMC10880001.
      Citations:    
    8. Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11; 28(12):1100-e1292. PMID: 37311055; PMCID: PMC10712705.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer. 2024 02 01; 130(3):400-409. PMID: 37864520; PMCID: PMC10841432.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther. 2023 Aug 01; 22(8):976-984. PMID: 37339271; PMCID: PMC10751575.
      Citations: 2     Fields:    Translation:Humans
    11. Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118. PMID: 37314501; PMCID: PMC10326142.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Altan M, Tu J, Milton DR, Yilmaz B, Tian Y, Fossella FV, Mott FE, Blumenschein GR, Stephen B, Karp DD, Meric-Bernstam F, Heymach JV, Naing A. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Cancer. 2023 09 01; 129(17):2685-2693. PMID: 37129197.
      Citations:    Fields:    Translation:Humans
    13. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718. PMID: 37058010; PMCID: PMC10150251.
      Citations:    Fields:    Translation:Humans
    14. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213. PMID: 37016732.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    15. Dagher H, Chaftari AM, Subbiah IM, Malek AE, Jiang Y, Lamie P, Granwehr B, John T, Yepez E, Borjan J, Reyes-Gibby C, Flores M, Khawaja F, Pande M, Ali N, Rojo R, Karp DD, Chaftari P, Hachem R, Raad II. Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. Elife. 2023 02 07; 12. PMID: 36748905; PMCID: PMC9977271.
      Citations: 4     Fields:    Translation:HumansCells
    16. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126. PMID: 36658425.
      Citations: 28     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    17. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409. PMID: 36288393; PMCID: PMC9843435.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    18. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18. PMID: 36751659; PMCID: PMC9888522.
      Citations:    
    19. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734. PMID: 36469840; PMCID: PMC10489509.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    20. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78. PMID: 36302890; PMCID: PMC9612600.
      Citations: 1     
    21. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367. PMID: 35999229; PMCID: PMC9399082.
      Citations:    
    22. Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol. 2022 07; 6:e2100512. PMID: 35834760; PMCID: PMC9307306.
      Citations:    Fields:    Translation:Humans
    23. Karp DD, Camidge DR, Infante JR, Ames TD, Price MR, Bryce AH, Jimeno J. Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. EClinicalMedicine. 2022 Jul; 49:101430. PMID: 35747193; PMCID: PMC9156977.
      Citations:    
    24. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep. 2022 05 24; 12(1):8701. PMID: 35610322; PMCID: PMC9130298.
      Citations:    Fields:    Translation:Humans
    25. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022 05; 10(5). PMID: 35618285; PMCID: PMC9125753.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    26. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A, Milton DR. Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 Apr; 40(2):463. PMID: 34731355; PMCID: PMC8993707.
      Citations:    Fields:    
    27. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A, Milton DR. Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2022 Apr; 40(2):461. PMID: 34705134; PMCID: PMC8993725.
      Citations:    Fields:    
    28. Vo HH, Cartwright C, Song IW, Karp DD, Nogueras Gonzalez GM, Xie Y, Karol M, Hitron M, Vining D, Tsimberidou AM. Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center. Cancers (Basel). 2022 Mar 04; 14(5). PMID: 35267638; PMCID: PMC8909492.
      Citations:    
    29. Thein KZ, Fu S, Janku F, Tsimberidou AM, Piha-Paul SA, Karp DD, Shah J, Gong J, Sulovic S, McQuinn L, Stephen BA, Colen RR, Carter BW, Meric-Bernstam F, Naing A, Milton DR. Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study. J Immunother Precis Oncol. 2022 Feb; 5(1):10-12. PMID: 35663832; PMCID: PMC9138422.
      Citations:    
    30. DiPeri TP, Demirhan M, Karp DD, Fu S, Hong DS, Subbiah V, Lim J, Ballester LY, Tayar JH, Suarez-Almazor ME, Javle M, Meric-Bernstam F. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol. 2022 Feb; 5(1):26-30. PMID: 35663835; PMCID: PMC9138421.
      Citations:    
    31. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, McQuinn L, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing A, Milton DR. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol. 2021 Dec 29; 10(1):59. PMID: 34965890; PMCID: PMC8715578.
      Citations:    
    32. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A, Milton DR. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 04; 40(2):290-299. PMID: 34562230; PMCID: PMC8993773.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    33. Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs. 2022 02; 40(1):124-133. PMID: 34559346.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    34. Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA, Hong DS. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs. 2022 02; 40(1):99-105. PMID: 34468905.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    35. Dumbrava EE, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open. 2021 10; 6(5):100230. PMID: 34479035; PMCID: PMC8414046.
      Citations: 1     Translation:Humans
    36. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. 2022 02; 20(1):e16-e24. PMID: 34362693.
      Citations:    Fields:    Translation:Humans
    37. Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Author response to Cunha et al. J Immunother Cancer. 2021 07; 9(7). PMID: 34315823; PMCID: PMC8317086.
      Citations:    Fields:    Translation:Humans
    38. Xu M, Tapia C, Hajjar J, Sabir S, Colen R, Nagarajan P, Aung PP, Gong J, Rodon J, Fu S, Stephen B, Roy-Chowdhuri S, Le H, Yang V, Zarifa A, Abdelsalam ME, Jhingran A, Javle M, Pant S, Carter B, Milton DR, Sun R, Karp DD, Koay EJ, Yang Y, Wistuba II, Hwu P, Meric-Bernstam F, Naing A. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol. 2021 May; 4(2):45-52. PMID: 35663531; PMCID: PMC9153261.
      Citations: 3     
    39. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther. 2021; 14:3037-3049. PMID: 33994796; PMCID: PMC8114359.
      Citations: 2     Translation:CTClinical Trials
    40. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A, Milton DR. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2021 10; 39(5):1357-1365. PMID: 33909232; PMCID: PMC8542012.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    41. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596. PMID: 33783054; PMCID: PMC8265355.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    42. Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing A. Overview of Ocular Side Effects of Selinexor. Oncologist. 2021 07; 26(7):619-623. PMID: 33728727; PMCID: PMC8265354.
      Citations: 1     Fields:    Translation:Humans
    43. Devarajan N, McGarvey JA, Scow K, Jones MS, Lee S, Samaddar S, Schmidt R, Tran TD, Karp DS. Cascading effects of composts and cover crops on soil chemistry, bacterial communities and the survival of foodborne pathogens. J Appl Microbiol. 2021 Oct; 131(4):1564-1577. PMID: 33825272; PMCID: PMC8519115.
      Citations: 1     Fields:    Translation:AnimalsCellsPHPublic Health
    44. Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4). PMID: 33849924; PMCID: PMC8051405.
      Citations: 9     Fields:    Translation:Humans
    45. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res. 2021 06 01; 27(11):3050-3060. PMID: 33771853; PMCID: PMC8172466.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    46. Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs. 2021 10; 39(5):1405-1410. PMID: 33770291.
      Citations: 7     Fields:    Translation:Humans
    47. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21. PMID: 33742104; PMCID: PMC7979841.
      Citations: 2     
    48. Hajjar J, Mendoza T, Zhang L, Fu S, Piha-Paul SA, Hong DS, Janku F, Karp DD, Ballhausen A, Gong J, Zarifa A, Peterson CB, Meric-Bernstam F, Jenq R, Naing A. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep. 2021 03 12; 11(1):5847. PMID: 33712647; PMCID: PMC7954807.
      Citations: 7     Fields:    Translation:HumansCells
    49. Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open. 2021 04; 6(2):100079. PMID: 33721621; PMCID: PMC7973128.
      Citations: 1     Translation:HumansCTClinical Trials
    50. Hong DS, Moore KN, Bendell JC, Karp DD, Wang JS, Ulahannan SV, Jones S, Wu W, Donoho GP, Ding Y, Capen A, Wang X, Bence Lin A, Patel MR. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874. PMID: 33495309.
      Citations: 5     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    51. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835. PMID: 33415580; PMCID: PMC8076052.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    52. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res. 2021 03; 19(3):395-402. PMID: 33323389.
      Citations: 1     Fields:    Translation:Humans
    53. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clin Cancer Res. 2021 03 01; 27(5):1247-1255. PMID: 33115815; PMCID: PMC9011198.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    54. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587. PMID: 33055173.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    55. Janku F, Zhang HH, Pezeshki A, Goel S, Murthy R, Wang-Gillam A, Shepard DR, Helgason T, Masters T, Hong DS, Piha-Paul SA, Karp DD, Klang M, Huang SY, Sakamuri D, Raina A, Torrisi J, Solomon SB, Weissfeld A, Trevino E, DeCrescenzo G, Collins A, Miller M, Salstrom JL, Korn RL, Zhang L, Saha S, Leontovich AA, Tung D, Kreider B, Varterasian M, Khazaie K, Gounder MM. Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. Clin Cancer Res. 2021 01 01; 27(1):96-106. PMID: 33046513.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    56. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 10; 8(2). PMID: 33097611; PMCID: PMC7590372.
      Citations: 3     Fields:    Translation:Humans
    57. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 09; 158(3):570-575. PMID: 32534809; PMCID: PMC7486997.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    58. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1). PMID: 32188704; PMCID: PMC7078933.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    59. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080. PMID: 32080210; PMCID: PMC7033174.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    60. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253. PMID: 31533818; PMCID: PMC6751592.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    61. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158. PMID: 31445783.
      Citations:    Fields:    
    62. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348. PMID: 30869638; PMCID: PMC6437608.
      Citations: 5     Fields:    Translation:Humans
    63. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. PMID: 30383888; PMCID: PMC6340722.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    64. Anderegg WRL, Konings AG, Trugman AT, Yu K, Bowling DR, Gabbitas R, Karp DS, Pacala S, Sperry JS, Sulman BN, Zenes N. Hydraulic diversity of forests regulates ecosystem resilience during drought. Nature. 2018 09; 561(7724):538-541. PMID: 30232452.
      Citations: 23     Fields:    Translation:Animals
    65. Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, Karp DD, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol. 2018; 2. PMID: 32913986; PMCID: PMC7446411.
      Citations: 4     Fields:    
    66. Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270. PMID: 30279957; PMCID: PMC6161801.
      Citations: 4     Fields:    
    67. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243. PMID: 30237864; PMCID: PMC6145698.
      Citations: 6     Fields:    
    68. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 11; 82(5):877-885. PMID: 30182147.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    69. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309. PMID: 30139837; PMCID: PMC6291334.
      Citations: 20     Fields:    Translation:Humans
    70. Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget. 2018 Jun 22; 9(48):28842-28848. PMID: 29989021; PMCID: PMC6034739.
      Citations: 3     Fields:    
    71. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. PMID: 29695765; PMCID: PMC5988803.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    72. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141. PMID: 29748008; PMCID: PMC6204221.
      Citations: 12     Fields:    Translation:Humans
    73. Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2018 04 01; 29(4):1076. PMID: 29253076; PMCID: PMC6888021.
      Citations: 1     Fields:    
    74. Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769. PMID: 29462132; PMCID: PMC5886120.
      Citations: 7     Fields:    Translation:Humans
    75. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963. PMID: 29162825; PMCID: PMC5698336.
      Citations: 14     Fields:    Translation:HumansCells
    76. Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423. PMID: 29047029; PMCID: PMC5908757.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    77. Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F, M?hrmann L. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188. PMID: 29051321; PMCID: PMC5754253.
      Citations: 63     Fields:    Translation:HumansCells
    78. Belinsky SA, Leng S, Wu G, Thomas CL, Picchi MA, Lee SJ, Aisner S, Ramalingam S, Khuri FR, Karp DD. Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence. Cancer Prev Res (Phila). 2017 Nov; 10(11):635-640. PMID: 28904059; PMCID: PMC5668184.
      Citations: 12     Fields:    Translation:HumansCells
    79. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173. PMID: 29152071; PMCID: PMC5675623.
      Citations:    Fields:    
    80. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162. PMID: 28729355; PMCID: PMC5902668.
      Citations: 1     Fields:    
    81. Leng S, Wu G, Klinge DM, Thomas CL, Casas E, Picchi MA, Stidley CA, Lee SJ, Aisner S, Siegfried JM, Ramalingam S, Khuri FR, Karp DD, Belinsky SA. Gene methylation biomarkers in sputum as a classifier for lung cancer risk. Oncotarget. 2017 Sep 08; 8(38):63978-63985. PMID: 28969046; PMCID: PMC5609978.
      Citations: 11     Fields:    
    82. Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656. PMID: 28536309; PMCID: PMC5600825.
      Citations: 27     Fields:    Translation:Humans
    83. Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806. PMID: 28430579; PMCID: PMC5464912.
      Citations: 4     Fields:    Translation:Humans
    84. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8). PMID: 28422758; PMCID: PMC5396533.
      Citations: 13     Fields:    
    85. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35. PMID: 28428884; PMCID: PMC5394629.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    86. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
    87. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Fr?h M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazi?res J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. PMID: 28447912; PMCID: PMC5559893.
      Citations: 100     Fields:    Translation:Humans
    88. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol. 2017 03 01; 28(3):642-650. PMID: 27993791; PMCID: PMC5834133.
      Citations: 26     Fields:    Translation:Humans
    89. Fujii T, Barzi A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Lenz HJ, Bardelli A, Janku F, Sartore-Bianchi A, Cassingena A, Veronese S, Siena S. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666. PMID: 28096270; PMCID: PMC5511562.
      Citations: 25     Fields:    Translation:Humans
    90. Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444. PMID: 27882721; PMCID: PMC5224847.
      Citations: 10     Fields:    Translation:Humans
    91. Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. 2017; 92(1):14-20. PMID: 27802448; PMCID: PMC5308283.
      Citations:    Fields:    Translation:Humans
    92. Bupathi M, Hajjar J, Bean S, Fu S, Hong D, Karp D, Stephen B, Hess K, Meric-Bernstam F, Naing A. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs. 2017 02; 35(1):59-67. PMID: 27687047; PMCID: PMC5896759.
      Citations: 1     Fields:    Translation:Humans
    93. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551; PMCID: PMC5355002.
      Citations: 137     Fields:    Translation:HumansCellsCTClinical Trials
    94. Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016 11; 27(11):2032-2038. PMID: 27573565; PMCID: PMC6267944.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    95. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485. PMID: 27466356.
      Citations: 39     Fields:    Translation:HumansCells
    96. Mengistu B, Ray D, Lockett P, Dorsey V, Phipps RA, Subramanian H, Atkins JT, El Osta B, Falchook GS, Karp DD. Innovative Strategies for Decreasing Blood Collection Wait Times for Patients in Early-Phase Cancer Clinical Trials. J Oncol Pract. 2016 07; 12(7):e784-91. PMID: 27328793; PMCID: PMC6366248.
      Citations: 1     Fields:    Translation:Humans
    97. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404. PMID: 27207774.
      Citations: 43     Fields:    Translation:HumansCells
    98. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701. PMID: 27197177.
      Citations: 109     Fields:    Translation:HumansCellsCTClinical Trials
    99. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7. PMID: 27014780; PMCID: PMC5978416.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    100. Al-Rohil RN, Tarasen AJ, Carlson JA, Wang K, Johnson A, Yelensky R, Lipson D, Elvin JA, Vergilio JA, Ali SM, Suh J, Miller VA, Stephens PJ, Ganesan P, Janku F, Karp DD, Subbiah V, Mihm MC, Ross JS. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer. 2016 Jan 15; 122(2):249-57. PMID: 26479420.
      Citations: 31     Fields:    Translation:Humans
    101. Karp DS, Mendenhall CD, Callaway E, Frishkoff LO, Kareiva PM, Ehrlich PR, Daily GC. Reply to Kirchhoff: Homogenous and mutually exclusive conservation typologies are neither possible nor desirable. Proc Natl Acad Sci U S A. 2015 Nov 03; 112(44):E5906. PMID: 26483508; PMCID: PMC4640779.
      Citations:    Fields:    
    102. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015 Oct 16; 15:713. PMID: 26474549; PMCID: PMC4609167.
      Citations: 20     Fields:    Translation:Humans
    103. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94. PMID: 26330075; PMCID: PMC4694960.
      Citations: 17     Fields:    Translation:Humans
    104. Karp DS, Mendenhall CD, Callaway E, Frishkoff LO, Kareiva PM, Ehrlich PR, Daily GC. Confronting and resolving competing values behind conservation objectives. Proc Natl Acad Sci U S A. 2015 Sep 01; 112(35):11132-7. PMID: 26283400; PMCID: PMC4568250.
      Citations: 5     Fields:    
    105. Wood SA, Karp DS, DeClerck F, Kremen C, Naeem S, Palm CA. Functional traits in agriculture: agrobiodiversity and ecosystem services. Trends Ecol Evol. 2015 Sep; 30(9):531-9. PMID: 26190137.
      Citations: 38     Fields:    
    106. Singleton PA, Moss J, Karp DD, Atkins JT, Janku F. The mu opioid receptor: A new target for cancer therapy? Cancer. 2015 Aug 15; 121(16):2681-8. PMID: 26043235.
      Citations: 29     Fields:    Translation:HumansAnimals
    107. Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J, Rodrigues HV. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9. PMID: 25902899.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    108. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018. PMID: 25669829; PMCID: PMC6279067.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    109. Falchook GS, Bastida CC, Stephens PJ, Miller VA, Gaido L, Jackson T, Karp DD, Ord??ez NG. Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 05 20; 34(15):e141-4. PMID: 25366691.
      Citations: 28     Fields:    Translation:Humans
    110. Karp DS, Judson S, Daily GC, Hadly EA. Molecular diagnosis of bird-mediated pest consumption in tropical farmland. Springerplus. 2014; 3:630. PMID: 25392800; PMCID: PMC4216319.
      Citations: 1     
    111. Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2014 Jul 01; 32(19):2059-66. PMID: 24888810; PMCID: PMC4067944.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    112. Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon G, Okawara G, Marks R, Frechette E, McCaskill-Stevens W, Lippman SM, Ruckdeschel J, Khuri FR. Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol. 2013 Nov 20; 31(33):4179-87. PMID: 24002495; PMCID: PMC3821010.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    113. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12; 306(14):1549-56. PMID: 21990298; PMCID: PMC4169010.
      Citations: 586     Fields:    Translation:Humans
    114. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer. 2011 Jan 04; 104(1):68-74. PMID: 21102589; PMCID: PMC3039819.
      Citations: 42     Fields:    Translation:Humans
    115. Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res. 2010 Sep 15; 16(18):4654-65. PMID: 20670944; PMCID: PMC2952544.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    116. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15. PMID: 20225329.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    117. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol. 2009 Nov; 4(11):1397-403. PMID: 19745765; PMCID: PMC2941876.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    118. Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer. 2009 Jul; 10(4):273-80. PMID: 19632947.
      Citations: 17     Fields:    Translation:Humans
    119. Oh Y, Taylor S, Bekele BN, Debnam JM, Allen PK, Suki D, Sawaya R, Komaki R, Stewart DJ, Karp DD. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009 Jul 01; 115(13):2930-8. PMID: 19441110.
      Citations: 42     Fields:    Translation:Humans
    120. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience. Oncology. 2009; 77(2):75-81. PMID: 19571599; PMCID: PMC2790774.
      Citations:    Fields:    Translation:Humans
    121. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009 May 20; 27(15):2516-22. PMID: 19380445.
      Citations: 111     Fields:    Translation:HumansCTClinical Trials
    122. Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. The changing face of phase 1 cancer clinical trials: new challenges in study requirements. Cancer. 2009 Apr 15; 115(8):1592-7. PMID: 19165808; PMCID: PMC2668727.
      Citations: 8     Fields:    
    123. Srivastava G, Rana V, Wallace S, Taylor S, Debnam M, Feng L, Suki D, Karp D, Stewart D, Oh Y. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients. J Thorac Oncol. 2009 Mar; 4(3):333-7. PMID: 19190519.
      Citations: 17     Fields:    Translation:Humans
    124. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 07; 301(1):39-51. PMID: 19066370; PMCID: PMC3682779.
      Citations: 719     Fields:    Translation:HumansCTClinical Trials
    125. William WN, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol. 2007 Aug; 2(8):745-50. PMID: 17762342.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    126. Karp DD. Selecting an Electronic Health Record System. J Oncol Pract. 2007 May; 3(3):172-173. PMID: 29455609; PMCID: PMC2793790.
      Citations: 1     Fields:    
    127. Lam P, Berman S, Thurer R, Ashiku S, DeCamp M, Goldstein M, Schumer S, Halmos B, Karp D, Coute D, Bergman M, Boyd-Sirard C, Ou SH, Muzikansky A, Woodard C, Huberman M. Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer. Clin Lung Cancer. 2006 Sep; 8(2):122-9. PMID: 17026813.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    128. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA, Picchi MA. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res. 2005 Sep 15; 11(18):6505-11. PMID: 16166426.
      Citations: 79     Fields:    Translation:HumansCells
    129. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst. 2005 Jan 19; 97(2):94-102. PMID: 15657339.
      Citations: 98     Fields:    Translation:Humans
    130. Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Bonomi P, P?rez-Soler R, Santab?rbara P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47. PMID: 15310767.
      Citations: 250     Fields:    Translation:HumansCTClinical Trials
    131. Glover D, Ibrahim J, Kirkwood J, Glick J, Karp D, Stewart J, Ewell M, Borden E, Eastern Cooperative Oncology Group. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003 Dec; 13(6):619-26. PMID: 14646626.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    132. Karp DD, Tsao AS, Kim ES. Nonsmall-cell lung cancer: chemoprevention studies. Semin Thorac Cardiovasc Surg. 2003 Oct; 15(4):405-20. PMID: 14710383.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    133. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003 Mar 06; 348(10):883-90. PMID: 12621132.
      Citations: 374     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    134. Tishler RB, Norris CM, Colevas AD, Lamb CC, Karp D, Busse PM, Nixon A, Frankenthaler R, Lake-Willcutt B, Costello R, Case M, Posner MR. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer. 2002 Oct 01; 95(7):1472-81. PMID: 12237916.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    135. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG. Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res. 2002 Jan 15; 62(2):528-34. PMID: 11809705.
      Citations: 52     Fields:    Translation:HumansCells
    136. Law A, Karp DD, Dipetrillo T, Daly BT. Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer. 2001 Jul 01; 92(1):160-4. PMID: 11443622.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    137. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001 Apr 18; 93(8):605-18. PMID: 11309437.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    138. Boiselle PM, Ernst A, Karp DD. Lung cancer detection in the 21st century: potential contributions and challenges of emerging technologies. AJR Am J Roentgenol. 2000 Nov; 175(5):1215-21. PMID: 11044010.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    139. Thurer RL, Thorsen A, Parker JA, Karp DD. FDG imaging of a pulmonary artery sarcoma. Ann Thorac Surg. 2000 Oct; 70(4):1414-5. PMID: 11081917.
      Citations: 3     Fields:    Translation:Humans
    140. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000 Jun; 18(12):2354-62. PMID: 10856094.
      Citations: 329     Fields:    Translation:HumansCTClinical Trials
    141. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5. PMID: 10623703.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    142. Wadler S, Atkins M, Karp D, Neuberg D, Haynes H, Dutcher JP. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991. Cancer J Sci Am. 1998 Jul-Aug; 4(4):261-8. PMID: 9689985.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    143. Hellman R, Neuberg DS, Wagner H, Grunnet M, Robins HI, Karp D, Flynn P, Adams G. A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392). J Neurooncol. 1998 Mar; 37(1):55-62. PMID: 9525838.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    144. Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Karp DD, Blum RH. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998 Jan 15; 82(2):292-300. PMID: 9445185.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    145. Karp DD. Lung cancer chemoprevention and management of carcinoma in situ. Semin Oncol. 1997 Aug; 24(4):402-10. PMID: 9280219.
      Citations:    Fields:    Translation:Humans
    146. Altuwairgi O, Papageorge MB, Karp DD. Maxillary chondroblastic sarcoma: presentation of two cases and a literature review. J Oral Maxillofac Surg. 1996 Nov; 54(11):1357-64. PMID: 8941190.
      Citations: 3     Fields:    Translation:Humans
    147. Karp DD, Atkins MB. Adoptive immunotherapy for nonsmall cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the above. Cancer. 1996 Jul 15; 78(2):195-8. PMID: 8673991.
      Citations:    Fields:    Translation:HumansCells
    148. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson AB. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 1996 Jun; 13(2):87-93. PMID: 9013471.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    149. Schiller JH, Pugh M, Kirkwood JM, Karp D, Larson M, Borden E. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res. 1996 Jan; 2(1):29-36. PMID: 9816086.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    150. Park SS, Karp DD, Karmody CS. Lingual necrosis as the initial symptom of small cell carcinoma. Otolaryngol Head Neck Surg. 1995 Jun; 112(6):782-4. PMID: 7777372.
      Citations:    Fields:    Translation:Humans
    151. Battey JF, Brown PH, Gritz ER, Hong WK, Johnson BE, Karp DD, Mulshine JL, Shaw GL, Shopland DR, Sunday ME, et al. Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop. Lung Cancer. 1995 Mar; 12(1-2):91-103. PMID: 7600036.
      Citations:    Fields:    Translation:Humans
    152. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol. 1995 Feb; 13(2):490-6. PMID: 7844610.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    153. Graham RA, Atkins MB, Karp DD, Wazer DE, Hackford AW. Local excision of rectal carcinoma. Early results with combined chemoradiation therapy using 5-fluorouracil and leucovorin. Dis Colon Rectum. 1994 Apr; 37(4):308-12. PMID: 8168408.
      Citations: 5     Fields:    Translation:Humans
    154. Middleton G, Karp D, Lee E, Cush J. Wegener's granulomatosis presenting as lower back pain with prostatitis and ureteral obstruction. J Rheumatol. 1994 Mar; 21(3):566-9. PMID: 8006905.
      Citations: 6     Fields:    Translation:Humans
    155. van der Riet P, Karp D, Farmer E, Wei Q, Grossman L, Tokino K, Ruppert JM, Sidransky D. Progression of basal cell carcinoma through loss of chromosome 9q and inactivation of a single p53 allele. Cancer Res. 1994 Jan 01; 54(1):25-7. PMID: 8261448.
      Citations: 13     Fields:    Translation:HumansCells
    156. Trehu EG, Isner JM, Mier JW, Karp DD, Atkins MB. Possible myocardial toxicity associated with interleukin-4 therapy. J Immunother Emphasis Tumor Immunol. 1993 Nov; 14(4):348-51. PMID: 8280718.
      Citations: 2     Fields:    Translation:Humans
    157. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med. 1993 Aug 19; 329(8):517-23. PMID: 8336750.
      Citations: 62     Fields:    Translation:HumansCells
    158. Daly BD, Mueller JD, Faling LJ, Diehl JT, Bankoff MS, Karp DD, Rand WM. N2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest. J Thorac Cardiovasc Surg. 1993 May; 105(5):904-10; discussion 910-1. PMID: 8487569.
      Citations: 5     Fields:    Translation:Humans
    159. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst. 1993 Mar 03; 85(5):388-94. PMID: 8094467.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    160. Atkins MB, Vachino G, Tilg HJ, Karp DD, Robert NJ, Kappler K, Mier JW. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol. 1992 Nov; 10(11):1802-9. PMID: 1403061.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    161. Truelson JM, Fisher SG, Beals TE, McClatchey KD, Wolf GT. DNA content and histologic growth pattern correlate with prognosis in patients with advanced squamous cell carcinoma of the larynx. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. Cancer. 1992 Jul 01; 70(1):56-62. PMID: 1606547.
      Citations: 7     Fields:    Translation:HumansCells
    162. Braunstein NS, Weber DA, Wang XC, Long EO, Karp D. Sequences in both class II major histocompatibility complex alpha and beta chains contribute to the binding of the superantigen toxic shock syndrome toxin 1. J Exp Med. 1992 May 01; 175(5):1301-5. PMID: 1569399; PMCID: PMC2119222.
      Citations: 7     Fields:    Translation:AnimalsCells
    163. Karp DD, Vaughan CW, Carter R, Willett B, Heeren T, Calarese P, Zeitels S, Strong MS, Hong WK. Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. A long-term follow-up report. Am J Clin Oncol. 1991 Aug; 14(4):273-9. PMID: 1713738.
      Citations: 12     Fields:    Translation:Humans
    164. Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991 06 13; 324(24):1685-90. PMID: 2034244.
      Citations: 505     Fields:    Translation:HumansCTClinical Trials
    165. Vokes EE, Dimery IW, Jacobs CD, Karp D, Molina A, Collier MA, Eble ML, Clendeninn NJ. A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer. Cancer. 1991 May 01; 67(9):2253-7. PMID: 2013031.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    166. Seabrook GR, Karp D, Schmitt DD, Bandyk DF, Towne JB. An outpatient anticoagulation protocol managed by a vascular nurse-clinician. Am J Surg. 1990 Nov; 160(5):501-5. PMID: 2240384.
      Citations: 7     Fields:    Translation:Humans
    167. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990 Sep 20; 323(12):795-801. PMID: 2202902.
      Citations: 200     Fields:    Translation:HumansCTClinical Trials
    168. Seder RH, Vaughan CW, Katz AE, Blanchard GC, Ulrich F, Oh SK, Willett BL, Karp DD, Doos WG. Clinical and laboratory changes following plasmapheresis in 12 patients with squamous cancer of the head and neck. Prog Clin Biol Res. 1990; 337:347-9. PMID: 2352992.
      Citations:    Fields:    Translation:Humans
    169. Cersosimo RJ, Calarese P, Karp DD. Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature. DICP. 1989 Nov; 23(11):876-7. PMID: 2688329.
      Citations: 2     Translation:Humans
    170. Cersosimo RJ, Carter RT, Matthews SJ, Coderre M, Karp DD. Acute cerebellar syndrome, conjunctivitis, and hearing loss associated with low-dose cytarabine administration. Drug Intell Clin Pharm. 1987 Oct; 21(10):798-803. PMID: 3428138.
      Citations: 2     Fields:    Translation:Humans
    171. Daly BD, Faling LJ, Gale ME, Jung-Legg Y, Snider GL, Karp DD, Chang HS. Staging with CT. Chest. 1986 Dec; 90(6):926-7. PMID: 3780338.
      Citations: 1     Fields:    Translation:Humans
    172. Cersosimo RJ, Karp DD. Adrenal corticosteroids as antiemetics during cancer chemotherapy. Pharmacotherapy. 1986 May-Jun; 6(3):118-27. PMID: 3526297.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    173. Licciardello JT, Cersosimo RJ, Karp DD, Hoffer SM, Paquette-Tello DA, Hong WK. Disturbing central nervous system complications following combination chemotherapy and prophylactic whole-brain irradiation in patients with small cell lung cancer. Cancer Treat Rep. 1985 Dec; 69(12):1429-30. PMID: 3000592.
      Citations: 2     Fields:    Translation:Humans
    174. Karp DD, Parker LM, Binder N, Tantravahi R, Smith BR, Ervin TJ, Canellos GP. Treatment of the blastic transformation of chronic granulocytic leukemia using high dose BCNU chemotherapy and cryopreserved autologous peripheral blood stem cells. Am J Hematol. 1985 Mar; 18(3):243-9. PMID: 2858155.
      Citations:    Fields:    Translation:HumansCells
    175. Hong WK, O'Donoghue GM, Sheetz S, Fofonoff S, Dorman EB, Welch J, Vaughan CW, Karp DD, Willett B, Strong S. Sequential response patterns to chemotherapy and radiotherapy in head and neck cancer: potential impact of treatment in advanced laryngeal cancer. Prog Clin Biol Res. 1985; 201:191-7. PMID: 4095110.
      Citations: 2     Fields:    Translation:Humans
    176. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology. 1985; 42(5):296-300. PMID: 3875817.
      Citations: 40     Fields:    Translation:Humans
    177. Tappe JP, Weitzman I, Liu S, Dolensek EP, Karp D. Systemic Mycobacterium marinum infection in a European hedgehog. J Am Vet Med Assoc. 1983 Dec 01; 183(11):1280-1. PMID: 6643246.
      Citations: 5     Fields:    Translation:AnimalsCells
    178. Griffin JD, Todd RF, Ritz J, Nadler LM, Canellos GP, Rosenthal D, Gallivan M, Beveridge RP, Weinstein H, Karp D, Schlossman SF. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91. PMID: 6571717.
      Citations: 14     Fields:    Translation:HumansCells
    179. Karp DD, Ervin TJ, Tuttle S, Gorgone BC, Lavin P, Yunis EJ. Pulmonary complications during granulocyte transfusions: incidence and clinical features. Vox Sang. 1982 Feb; 42(2):57-61. PMID: 7064430.
      Citations: 6     Fields:    Translation:HumansCells
    180. Karp DD, Beck JR, Cornell CJ. Chronic granulocyte leukemia with respiratory distress. Efficacy of emergency leukapheresis. Arch Intern Med. 1981 Sep; 141(10):1353-4. PMID: 6943985.
      Citations:    Fields:    Translation:HumansPHPublic Health
    181. Ervin TJ, Karp DD, Weichselbaum RR, Posner MR, Fabian RL, Miller D. Role of chemotherapy in the multidisciplinary approach to advanced head and neck cancer: potentials and problems. Ann Otol Rhinol Laryngol. 1981 Sep-Oct; 90(5 Pt 1):506-11. PMID: 7030176.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    182. Moore FD, Osteen RT, Karp DD, Steele G, Wilson RE. Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg. 1981 Apr; 116(4):405-7. PMID: 6971083.
      Citations: 6     Fields:    Translation:Humans
    183. Kufe DW, Beardsley P, Karp D, Parker L, Rosowsky A, Canellos G, Frei E. High-dose thymidine infusions in patients with leukemia and lymphoma. Blood. 1980 Apr; 55(4):580-9. PMID: 6965595.
      Citations: 12     Fields:    Translation:HumansCells
    184. Mills RC, Maurer LH, Forcier RJ, Grace WR, Burke GP, Karp DD, Smith RC, Mcintyre OR, Bean C. Clinical trial of combined therapy with adriamycin and cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1977 May-Jun; 61(3):477-9. PMID: 872146.
      Citations:    Fields:    Translation:Humans
    185. Perlin E, Engeler JE, Edson M, Karp D, McIntire KR, Waldmann TA. The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. Cancer. 1976 Jan; 37(1):215-9. PMID: 55299.
      Citations: 5     Fields:    Translation:Humans
    186. TP53 alterations correlate with response to VEGF/VEGFR inhibitors. Molecular Cancer Therapeutics. 15:2475-2485.
    187. BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Molecular Cancer Therapeutics. 15:1397-1404.
    188. Erratum. British Journal of Cancer. 107:2024.
    189. Phase III chemoprevention trial of selenium supplementation in persons with resected stage I non-small-cell lung cancer. Clinical Advances in Hematology and Oncology. 3:313-315.
    190. Cancer therapy directed by comprehensive genomic profiling. Cancer Research. 76:3690-3701.
    191. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology (Switzerland).
    192. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.
    193. Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer. Journal of Clinical Oncology. 34:e141-e144.
    194. Survival of patients with metastatic leiomyosarcoma. Cancer Medicine. 5:3437-3444.
    195. Individuals with colonic adenomas harbor more p53-specific DNA strand breaks in the 'normal' colonic mucosa than controls. HW balk. FASEB Journal. 11.
    196. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology. 1-5.
    197. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials. Investigational New Drugs. 1-9.
    198. Carcinogenesis from the perspective of targeted therapy.
    199. Selecting an electronic health record system. Journal of Oncology Practice. 3:172-173.
    200. Lung cancer. Primary Care Update for Ob/Gyns. 10:87-94.
    201. An association between the risk of cancer and mutations in the hras1 minisatellite locus. Diagnostic Molecular Pathology. 3:215.
    202. Handbook of targeted cancer therapy.
    203. Targets by organ site.
    204. Innovative strategies for decreasing blood collection wait times for patients in early-phase cancer clinical trials. Journal of Oncology Practice. 12:e784-e791.
    205. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 6:26886-26894.
    206. Preface.
    207. Modifications of techniques for storage and reinfusion of chronic granulocytic leukemia (CGL) peripheral blood stem cells (BSC). 683.
    KARP's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (612)
    Explore
    _
    Co-Authors (175)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _